Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Docetaxel Guided by mGSTP1 in mCRPC
NCT04918810Phase 2Terminated
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by ANZUP Cancer Trials Group. Primary endpoint: Radiographic Progression-Free Survival at 3.5 years. Started Jul 2022; status: terminated.
02
Drugs
docetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04918810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918810.